3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Celldex Therapeutics Inc

Celldex Therapeutics (CLDX) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Celldex Therapeutics Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

9 Nov, 2026

Barzolvolimab phase III results

  • Phase III CSU results showed complete response in a majority of patients, prospective angioedema clearing at 12 weeks, and similar responses in omalizumab-refractory patients.

  • One regimen requires seven dosing days per year; HCPs highlighted rapid, durable responses that deepen over time, severe disease with angioedema, and biologic-refractory patients as key differentiators.

  • Phase II follow-up showed 41% of patients remained in complete response seven months after their last dose; phase III off-therapy durability data will follow treatment through 52 weeks and subsequent follow-up.

  • The overall safety profile was described as favorable; common KIT-mediated adverse events were mostly mild to moderate and expected to reverse, while serious and grade 3/4 event rates matched placebo.

  • Two phase III cases were adjudicated as probable anaphylaxis, both after the first barzolvolimab dose; a separate adjudicated anaphylaxis case occurred on placebo.

Regulatory and data milestones

  • BLA submission is guided for 2027, using the full 52-week data; the goal is to bring the therapy to patients as quickly as possible.

  • At AAAAI in February 2027, the planned presentation will cover 24-week efficacy, including primary and key secondary endpoints, 12- and 24-week results, and time course.

  • Additional presentations on secondary and exploratory endpoints are planned in the coming months; phase III off-therapy follow-up will come after the 52-week treatment period.

  • CIndU phase III trials are enrolling; further guidance is expected in the next few months. Atopic dermatitis data are expected by year-end, from a moderately severe population that allows prior therapies, including biologics.

Market and commercialization

  • In the U.S., an estimated 30% of CSU prevalence is diagnosed, and fewer than 20% of diagnosed patients clinically eligible for advanced therapy receive one.

  • Barzolvolimab is positioned for first-line patients with severe disease or angioedema, estimated at at least 25% of first-line patients, and as a second-line option for patients with ongoing symptoms.

  • Other therapies have complete response rates of 30%–38%; one-year real-world attrition for patients starting omalizumab or dupilumab is 50%, supporting a substantial second-line opportunity.

  • Preliminary payer discussions support a premium, value-based pricing strategy; commercial preparations include expanding the MSL team and building market analytics, brand, and payer teams.

  • Payer exchange under PIE is anticipated in H1 2027; infrastructure development is described as disciplined, data-based, milestone-driven, and focused on high-value prescriber accounts.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Celldex Therapeutics